Skip to main content

Table 2 Characteristics of antiretroviral treatment-experienced HIV/HBV Co-infected patients with undetectable HBVDNA compared to those with detectable HBV DNA

From: Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients

Characteristic

HBV DNA < 20

HBV DNA ≥ 20

P-value T test

P-value Wilcoxon rank sum test

IU/mL (N = 64)

IU/mL (N = 88)

Mean (SD) age (years)

42.6 (9.6)

42.7 (9.5)

0.928

0.701

Mean (SD) weight (kg)

65.9 (13.7)

63.5 (12.2)

0.262

0.326

Mean (SD) BMI (kg/m2)

24.5 (4.6)

23.9 (4.7)

0.415

0.432

Mean (SD) CD4 count (cells/uL)

539 (257)

478 (358)

0.244

0.157

 

n (%)

n (%)

P value Chi square

P value Fisher

Male sex

30 (46.9 %)

34 (53.1 %)

0.019

0.021

Ethnicity

  

0.656

0.679

 Akan

43 (59.7 %)

29 (40.3 %)

  

 Ewe

14 (48.3 %)

15 (51.7 %)

  

 Ga

13 (65.0 %)

7 (35.0 %)

  

 Other

18 (58.1 %)

13 (41.9 %)

  

WHO HIV stage

  

0.086

0.095

 1

24 (63.2 %)

14 (36.8 %)

  

 2

21 (58.3 %)

15 (41.7 %)

  

 3

37 (60.7 %)

24 (39.3 %)

  

 4

4 (26.7 %)

11 (73.3 %)

  

HBeAg positive

0

28 (100.0 %)

<0.0001

<0.0001

HBeAb positive

85 (69.7 %)

37 (30.3 %)

<0.0001

<0.0001

HB eAg/E Ab combination

  

<0.0001

<0.0001

HBeAg positive/Ab negative

0

25 (100.0 %)

  

HBeAg negative/Ab positive

85 (71.4 %)

34 (28.6 %)

  

HBeAg negative/Ab negative

3 (60.0 %)

2 (40.0 %)

  

HBeAg positive/Ab positive

0

3 (100.0 %)

  

HBcIgM positive

0

4 (100.0 %)

0.0175

0.030

Alanine aminotransferase

  

0.0001

0.0002

 Normal (5-40 U/L)

79 (65.8 %)

41 (34.2 %)

  

 Elevated > ULN

9 (28.1 %)

23 (71.9 %)

  

Aspartate aminotransferase

  

0.0004

0.0008

 Normal (5-50 U/L)

81 (64.3 %)

45 (35.7 %)

  

Elevated > ULN

7 (26.9 %)

19 (73.1 %)

  

Characteristic

HBV DNA < 20 IU mL-1

HBV DNA ≥ 20 IU mL-1

P value Chi square

P value Fisher

n (%)

n (%)

Albumin

  

0.096

0.119

 Normal (36-50 g/L)

72 (61.5 %)

45 (38.5 %)

  

 Low < LLN

16 (45.7 %)

19 (54.3 %)

  

Initial ART contain

  

0.971

1.000

 3TC (n = 100)

42 (42.0 %)

58 (58.0 %)

  

 3TC + TDF (n = 52)

22 (42.3 %)

30 (57.7 %)

  

Duration on ART

  

0.969

0.972

<1 year

3 (75.0 %)

1 (25.0 %)

  

 1 – 2 years

22 (57.9 %)

16 (42.1 %)

  

 2 – 3 years

12 (57.1 %)

9 (42.9 %)

  

  > 3 years

51 (57.3 %)

38 (42.7 %)

  

Ever forgotten meds?

26 (72.2 %)

10 (27.8 %)

0.046

 

Do you take meds on time?

8 (50.0 %)

8 (50.0 %)

0.499

 

Stop taking meds due to illness?

9 (75.0 %)

3 (25.0 %)

0.211

 

Forgotten meds last weekend?

10 (71.4 %)

4 (28.6 %)

0.282

 

Number of times not taken meds last week?

  

--

 

 0

35 (61.4 %)

22 (38.6 %)

  

 1 - 2

7 (70.0 %)

3 (30.0 %)

  

 3 – 5

4 (66.7 %)

2 (33.3 %)

  

 more than 5

1 (33.3 %)

2 (66.7 %)

  
  1. BMI body mass index
  2. HBeAg/Ab Hepatitis B e Antigen/Antibody
  3. HBcIgM Hepatitis B core IgM
  4. 3TC lamivudine
  5. TDF tenofovir
  6. ULN upper limit of normal
  7. LLN lower limit of normal
  8. ART anti-retroviral therapy